{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:06Z","timestamp":1790720346448,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["IZLIZ3_200253\/1"],"award-info":[{"award-number":["IZLIZ3_200253\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jdcr.2024.09.021","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T18:06:03Z","timestamp":1728756363000},"page":"23-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management"],"prefix":"10.1016","volume":"54","author":[{"given":"Gabriela","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Doms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begonia","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Boulinguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jdcr.2024.09.021_bib1","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jdcr.2024.09.021_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/14740338.2019.1643837","article-title":"A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma","volume":"18","author":"Afifi","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.jdcr.2024.09.021_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.09.021_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1684\/ejd.2017.3103","article-title":"Mogamulizumab-induced toxicoderma-like eruptions and autoimmune hepatitis successfully treated with azathioprine in adult T-cell leukaemia\/lymphoma","volume":"27","author":"Nishizawa","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"24","key":"10.1016\/j.jdcr.2024.09.021_bib5","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and S\u00e9zary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jdcr.2024.09.021_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1684\/ejd.2021.4002","article-title":"Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: three cases","volume":"31","author":"Algarni","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jdcr.2024.09.021_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdcr.2023.08.044","article-title":"Alopecia areata-like presentations with mogamulizumab therapy","volume":"41","author":"Kincaid","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jdcr.2024.09.021_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with S\u00e9zary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.09.021_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12185-018-2456-9","article-title":"Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration","volume":"107","author":"Hosoi","year":"2018","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.jdcr.2024.09.021_bib10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.09.021_bib11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2017.12.068","article-title":"Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy","volume":"78","author":"Martinez-Escala","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262400393X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262400393X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:38:32Z","timestamp":1778841512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235251262400393X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":11,"alternative-id":["S235251262400393X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.021","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}